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Abstract
Introduction: Paraganglioma (PGL) is a rare neuroendocrine tumor. Currently, the malignancy is defined as the presence of
metastatic spread at presentation or during follow-up. Several gene mutations are listed in the pathogenesis of PGL, among which
succinate dehydrogenase (SDHX), particularly the SDHB isoform, is the main gene involved in malignancy. A 55-year-old male
without evidence of catecholamine secretion had surgery for PGL of the urinary bladder. After 1 year, he showed a relapse of disease
and demonstrated malignant PGL without evidence of catecholamine secretion with a germline heterozygous mutation of succinate
dehydrogenase B (SDHB). After failure of a second surgery for relapse, he started medical treatment with sunitinib daily but
discontinued due to serious side effects. Cyclophosphamide, vincristine, and dacarbazine (CVD) chemotherapeutic regimen stopped
the disease progression for 7 months.
Conclusion:Malignant PGL is a very rare tumor, and SDHBmutations must be always considered in molecular diagnosis because
they represent a critical event in the progression of the oncological disease. Currently, there are few therapeutic protocols, and it is
often difficult, as this case demonstrates, to decide on a treatment option according to a reasoned set of choices.
Abbreviations: CVD = cyclophosphamide, vincristine and dacarbazine, HIF-1a = hypoxia inducible factor 1 alpha, PGL =
paraganglioma, SDH = succinate dehydrogenase, VEGF = vasoendothelial growth factor.
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Paraganglioma (PGL) or extra-adrenal pheochromocytoma is a
rare neuroendocrine tumor arising from chromaffin cells in many
different paraganglia in the body. The PGL affects approximately
2 to 5 patients per million per year and can occur between 30 and
50 years of age, with a similar gender affinity. PGLs are classified
as sympathetic or parasympathetic, depending on their origin.
Thoraco-abdomino-pelvic PGLs are of sympathetic origin andEditor: N/A.
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1produce catecholamines, their metabolites and other peptides; in
contrast, PGLs of the head and neck are of parasympathetic
origin and do not usually produce catecholamines.[1] A proper
histological recognition of the potential malignancy of these
tumors is not yet available, although a scoring system based on
microscopic morphology and clinical features has been pro-
posed.[2] Malignancy is involved in approximately 10% of PGLs
and is unfortunately established by metastatic spread. Currently,
genetic studies attribute an etiopathogenic role to a mutation of
succinate dehydrogenase complex subunits (SDHs) in an
increasing number of PGLs. Familial PGL syndromes are
autosomal dominant inherited diseases that are caused by
mutations in SDHX genes and have been classified as PGL1,
PGL2, PGL3, PGL4, and PGL5 based on mutations in SDHD,
SDHAF2, SDHC, SDHB, and SDHA, respectively.[3] The SDHB
mutation in PGL4 is associated with an increased risk of
malignancy. The morbidity associated with these tumors is
related mainly to their metastatic potential.[4] Here, we report a
case of a male patient who was affected by sporadic nonsecreting
malignant paraganglioma of the urinary bladder with a PGL4
syndrome carrier of a SDHB heterozygous germline mutation.
The patient was treated with 2 therapeutic regimen options,
which had different results. Preliminary evidence indicates that
PGL carrying SDHB mutations have a potential role in the
prediction of response to antiangiogenic therapy. In a retrospec-
tive study,[5] most of the patients who exhibited a positive
response to sunitinib therapy were SDHB mutation carriers, and
some of them exhibited a lasting response up to 2 years later.
Stigliano et al. Medicine (2018) 97:30 MedicineHowever, we obtained in this case, a significant result with the
cyclophosphamide-vincristine-dacarbazine (CVD) chemothera-
py scheme. It shows that genetics plays a key role in diagnosis and
follow up program but cannot still drive a therapeutic choice.Figure 1. 18FDG PET/CT whole body: pathological uptake in lymph nodes of
right iliac region (A), particular of right iliac region (B).
Table 1
First treatment: sunitinib 50mg administered orally for 4 months,
then reduced to 25mg for other 2 months.
Regimen protocols Duration of administration
Sunitinib 50mg per day 4 months
25mg per day 2 months
Every 28 days:
Day 1 750 mg/m2 cyclophosphamide 4 months
1.4 mg/m2 vincristine
600 mg/m2 dacarbazine
Day 2 600 mg/m2 dacarbazine
Day 1 187.5 mg/m2 cyclophosphamide 5 months
0.35 mg/m2 vincristine
150 mg/m2 dacarbazine
Day 2 150 mg/m2 dacarbazine
Second therapeutic regimens: cyclophosphamide 750mg/m2, vincristine 1.4mg/m2, and dacarbazine
600mg/m2 (CVD) in the first day and dacarbazine 600mg/m2 next day every 28 days for the first 4
months and reduced by 25% in the following 5 months in nine months total.2. Case report and methods
The patient’s family history included tireopathy, dyslipidaemia,
hypertension, and oncological disease, such as bladder cancer
(father), ovarian cancer (mother), and gastric cancer (maternal
grandfather). Physiological history was negative. The patient, 55-
year-old male of Caucasian ethnicity coming from Central Italy,
suffered from chronic obstructive bronchopneumopathy, reflux
oesophagitis, and colon diverticulosis. Furthermore, many years
ago, he had a left breast adenoma and colon poliposis removed
endoscopically.
He went to an endocrinology outpatient clinic because a year
previously, following a hematuria and abdominal pain, he had
surgery for a PGL of the urinary bladder, 7cm of maximum
diameter, Ki67 8% to 10%, with positive immunohistochemical
staining for chromogranin A, synaptophysin, neuron specific
enolase and S100 protein.
The objective examination was negative, and he had a normal
blood pressure and heart beat.
The assays of a urinary 24-hour sample of metanephrines and
normetanephrines were negative (35.5mcg/24h and 8.1mcg/24
h, respectively). Chromogranin A level was negative (32mcg/L).
Molecular analysis of the SDHB gene identified a germline
heterozygous variant mutation in exon 7, c.689G>A p.
Arg230His, which has been described as being associated with
PGL4 syndrome and considered pathogenetic.[6] The first 18FDG
PET/TC performed showed suspicious lymph nodes (SUV 8.13)
in the right iliac region (Fig. 1), and surgical removal was positive
for cromaffin tissue. Follow-up at 3 months with 18FDG PET/TC
showed a new uptake in a large lymph node in the right iliac
region (30mm) and in the aorto-caval region (9mm). MIBG scan
was negative. The patient was successfully treated with a second
surgical excision of the iliac and aorto-caval lymph nodes,
resulting from metastasis. A 18FDG PET/TC after 4 months
demonstrated a worsening of metastatic spread, with a positive
uptake of lymph nodes in mediastinum, in the aorto-caval region,
the right iliac and inguinal region and the 7/8 liver segment.
The patient started antiangiogenic therapy with sunitinib
orally, 50mg flat per day. Treatment was associated with severe
gastrointestinal side effects, which led to reducing the dose to 25
mg after 4 months of treatment (Table 1). TC whole body
performed 6 months after starting of the sunitinib treatment
documented disease progression, which consisted of a volumetric
and numeric increase of over and under diaphragmatic lymph
nodes (Fig. 2), with evidence of lung, liver and bone metastatic
lesions, which were also documented with scintigraphy.
Therefore, it was decided to start a chemotherapeutic treatment
consisting of a combination of cyclophosphamide 750mg/m2,
vincristine 1.4mg/m2, and dacarbazine 600mg/m2 (CVD) for the
first 4 months and reduced by 25% in the following 5 months for
a total of 9 months (Table 1). This treatment schedule led to
stabilizing the disease and subjective clinical benefit. Following a
close follow-up, after 9 months of consecutive cycles of
chemotherapy, the patient did not have disease progression for
7 months stopping treatment, when a TC whole body showed
progression of the disease with the appearance of lumbar aortic
lymphadenopathies. The clinical and radiological pictures
indicated that the chemotherapy treatment should be resumed2according to the previous scheme. At 3 months after the onset of
treatment, TC reported a further progression of the disease due to
para-aortic and right iliac lymph nodes. Currently, the patient is
following the previous CVD schedule treatment with a relative
benefit in terms of disease progression. Written consent for
publishing this case report was obtained from the patient.
Figure 2. TC whole body: radiological evidence of disease progression. (A)
Pathological over diaphragmatic lymph nodes, arrow indicates prevascular
lymph nodes, triangle indicates lymph nodes in the Barety region. (B)
Pathological under diaphragmatic lymph nodes, circle indicates para-aortic,
paracaval and intercavo-aortic lymph nodes that include cava vein, aorta and,
right ureter.
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Nonsecreting paragangliomas are typically associated with head
and neck parasympathetic PGLs.[1] The incidence of malignant
PGLs is <1 million people/year. The malignancy of phaeochro-
mocytoma and PGL is estimated to be approximately 10% to
20%, and it is more common in sympathetic PGLs than in
phaeochromocytomas.[7] PGL carriers with a mutation involving
the SDHB gene are considered to potentially be at risk of
malignancy, and a close biochemical and imaging follow-up must
be reserved for them. SDHX inactivation is considered to be a
cause of a pseudo-hypoxic response due to an accumulation of
metabolites that are involved in the activation of the Hypoxia
Inducible Factor 1 alpha (HIF-1a) pathway, resulting in amarked
increase in neoangiogenesis and the expression of both vaso-
endothelial growth factor (VEGF) and its receptors in the
neoplastic tissues.[8] The close follow-up program and molecular
analysis that patients affected by PGL must undergo are crucial,
as this case demonstrates, especially because of its unusual
presentation that is not associated with catecholamine secretion.
The treatment of choice typically consists of the complete surgical
removal of the tumor. Therapeutic strategies for malignant PGLs
are lacking. Most of them are derived from retrospective studies3with few patients included or anecdotal case reports. In this case,
treatment posed further difficulties due to the lack of hormonal
secretion. Indeed, after surgery failure, the only therapeutic
chance was placed on medical treatment because the use of a
radiopharmaceutical targeted agent was not indicated. Therapy
options have been discussed in the setting of expert multidisci-
plinary meetings including endocrinologists, oncologists, radiol-
ogists and nuclear medicine physicians. SDHB-mutated tumors
promote the angiogenic pathway and activate genes that can
promote the epithelial-mesenchymal transition associated with
metastatic invasiveness.[9] The encouraging response related to
sunitinib with manageable toxicity in some patients affected by
metastatic PGL[10] encouraged us to start treatment with this
antiangiogenic drug (Table 1). As described, we noticed the same
side effect, especially in the gastrointestinal tract, even when the
dose was reduced significantly. Unfortunately, this treatment in
this case did not induce tumor growth arrest. Therefore, for the
progression of the disease, the patient started the CVD
chemotherapy regimen (Table 1). CVD was well tolerated by
the patient, without any evidence of side effects. This combina-
tion was able to induce tumor growth arrest without evidence of
disease progression and with subjective clinical benefit. These
results are in accordance with a recent study, which revealed that
47% of the treated patients showed a radiological tumor
response and disease stabilization with a gain in progression-free
survival.[11]
In conclusion, sympathetic PGL tumors are associated with a
higher rate of malignancy and lower overall survival rates. They
often are characterized by high secretory activity. This very rare
case of urinary bladder PGL4 syndrome in a patient with a
germline SDHB mutation highlights the need to classify these
tumors both genetically and histologically to differentiate benign
from malignant PGLs. Currently, the experience coming from
this case report suggests that all PGLs should be screened by
molecular analysis and that the follow up must be very close in
germline SDHB-mutated tumors. The lack of knowledge about
the histological behavior and natural history of the disease makes
clinical management of PGL a great challenge for endocrinol-
ogists. Prospective studies are needed to develop a flowchart and
therapeutic strategies.Author contributions
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